Evidence map›Paper›PMID 24781901›Full record

ArticleThe ISME journal2014

Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism.

Maomeng Tong, Ian McHardy, Paul Ruegger, Maryam Goudarzi, Purna C Kashyap, Talin Haritunians, Xiaoxiao Li, Thomas G Graeber, Emma Schwager, Curtis Huttenhower and 5 more

Open access · hybridAbstract read
In one paragraph

Article in The ISME journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 1 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Host-pathobiont interactions in Crohn's disease.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Maomeng TongDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Ian McHardyDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Paul RueggerDepartment of Plant Pathology and Microbiology, University of California, Riverside, CA, USA.
Maryam GoudarziDepartment of Biochemistry and Molecular and Cellular Biology, Georgetown University, Washington, DC, USA.
Purna C KashyapDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Talin HarituniansF. Widjaja Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Xiaoxiao LiF. Widjaja Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Thomas G GraeberDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Emma SchwagerBiostatistics Department, Harvard School of Public Health, Boston, MA, USA.
Curtis HuttenhowerBiostatistics Department, Harvard School of Public Health, Boston, MA, USA.
Albert J FornaceDepartment of Biochemistry and Molecular and Cellular Biology, Georgetown University, Washington, DC, USA.
Justin L SonnenburgDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Dermot P B McGovernF. Widjaja Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
James BornemanDepartment of Plant Pathology and Microbiology, University of California, Riverside, CA, USA.
Jonathan Braun1] Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA [2] Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USCedars-Sinai Medical Center · USGeorgetown University · USHarvard University · USStanford University · USUniversity of California, Riverside · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Using polygenic scores to enhance both variant discovery, and understanding of functional consequences of genetic variation in IBD.P01DK046763 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI TARGAN, STEPHAN R. · 1992 to 2020
$31.1M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
Utilizing the Phenomics of IBD to Enhance Gene DiscoveryU01DK062413 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Dermot Patrick McGovern · 2002 to 2026
$12.2M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Role of Mucin-type O-glycans in Intestinal InflammationR01DK085691 · NIDDK · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI David Casero, Lijun Xia · 2010 to 2026
$6.2M
Joint Interdisciplinary Training Program in Biostatistics & Computational BiologyT32GM074897 · NIGMS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUTTENHOWER, CURTIS, LIN, XIHONG · 2005 to 2019
$3.7M
Characterizing the gut microbial ecosystem for diagnosis and therapy in IBDU54DE023798 · NIDCR · BROAD INSTITUTE, INC. · PI HUTTENHOWER, CURTIS, XAVIER, RAMNIK J · 2013 to 2014
$3.0M
Identifying Microorganisms involved in Human Health and Disease ProcessesR01AI078885 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI BORNEMAN, JAMES · 2008 to 2011
$1.4M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1TR000124NCI NIH HHS P30 CA016042NCI NIH HHS P30 CA051008NCI NIH HHS P30-CA051008NCI NIH HHS R35 CA197449NCRR NIH HHS UL1 RR033176NIAID NIH HHS AI078885NIAID NIH HHS R01 AI078885NIDCR NIH HHS U54 DE023798NIDDK NIH HHS DK046763NIDDK NIH HHS DK062413NIDDK NIH HHS DK08569NIDDK NIH HHS P01 DK046763NIDDK NIH HHS R01 DK085691NIDDK NIH HHS U01 DK062413NIGMS NIH HHS T32 GM074897
6 · The paper itself

Abstract

Fucosyltransferase 2 (FUT2) is an enzyme that is responsible for the synthesis of the H antigen in body fluids and on the intestinal mucosa. The H antigen is an oligosaccharide moiety that acts as both an attachment site and carbon source for intestinal bacteria. Non-secretors, who are homozygous for the loss-of-function alleles of FUT2 gene (sese), have increased susceptibility to Crohn's disease (CD). To characterize the effect of FUT2 polymorphism on the mucosal ecosystem, we profiled the microbiome, meta-proteome and meta-metabolome of 75 endoscopic lavage samples from the cecum and sigmoid of 39 healthy subjects (12 SeSe, 18 Sese and 9 sese). Imputed metagenomic analysis revealed perturbations of energy metabolism in the microbiome of non-secretor and heterozygote individuals, notably the enrichment of carbohydrate and lipid metabolism, cofactor and vitamin metabolism and glycan biosynthesis and metabolism-related pathways, and the depletion of amino-acid biosynthesis and metabolism. Similar changes were observed in mice bearing the FUT2(-/-) genotype. Metabolomic analysis of human specimens revealed concordant as well as novel changes in the levels of several metabolites. Human metaproteomic analysis indicated that these functional changes were accompanied by sub-clinical levels of inflammation in the local intestinal mucosa. Therefore, the colonic microbiota of non-secretors is altered at both the compositional and functional levels, affecting the host mucosal state and potentially explaining the association of FUT2 genotype and CD susceptibility.

Indexed as

MicrobiotaPolymorphism, GeneticAdultAgedAnimalsBacteriaCrohn DiseaseEnergy MetabolismFemaleFucosyltransferasesGalactoside 2-alpha-L-fucosyltransferaseHumansIntestinal MucosaMaleMetabolomeMetagenomeFucosyltransferasesGalactoside 2-alpha-L-fucosyltransferaseProteome

Identifiers

PMID24781901
PMCPMC4992076
OpenAlexW2117088514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.